For decades, HIV treatment<\/a> has been one of modern medicine\u2019s most remarkable success stories. Antiretroviral therapy (ART) has transformed HIV from a fatal diagnosis into a manageable chronic condition. Today, millions of people on ART can live long, healthy lives and maintain undetectable viral loads that cannot be transmitted.<\/p>\n But ART is not a cure. It requires lifelong commitment, daily medication, consistent healthcare access, and carries the burden of stigma and side effects for some. The global scientific community has long searched for a better solution \u2014 ideally, one that could eliminate HIV or allow the immune system to suppress it without constant treatment.<\/p>\n This year, a trial based in Durban, South Africa delivered one of the most promising results we have ever seen. In what is being called a major breakthrough, researchers achieved long-term ART-free viral suppression in several women living with HIV. This marks a pivotal moment in the journey toward a functional cure<\/a> \u2014 where the virus is controlled without daily medication \u2014 and potentially, one day, a sterilizing cure that clears the virus completely.<\/p>\n This article explores what the Durban trial discovered, why it matters, and how it may shape the future of HIV cure science \u2014 not only in South Africa, but worldwide.<\/p>\n South Africa is home to the highest number of people living with HIV globally, with more than 7.5 million affected. It is also a leader in HIV prevention<\/a>, known for its large-scale treatment programs, cutting-edge research institutions, and tireless community-driven activism. This makes it more than just a location \u2014 it is a critical driver of progress in the global HIV fight.<\/p>\n Unlike North America and Europe, where most HIV studies have traditionally taken place, South Africa deals primarily with HIV-1 Subtype C<\/strong>. This strain is biologically different from Subtype B, which dominates Western research. Subtype C has unique characteristics in viral replication and immune evasion, making it essential to study in its native context.<\/p>\n Research in South Africa also brings attention to demographics that have long been overlooked. While HIV cure studies have historically focused on men from high-income countries, the recent Durban trial centered on cisgender women aged 18 to 23<\/strong> \u2014 a group that is disproportionately affected by HIV in Sub-Saharan Africa but underrepresented in clinical research.<\/p>\n South African institutions such as the Africa Health Research Institute (AHRI)<\/a>, CAPRISA<\/a>, and the Wits Reproductive Health Institute<\/a> are now internationally recognized hubs for HIV innovation. The country is not only confronting its own epidemic but also reshaping how HIV research is done across the globe \u2014 inclusively, ethically, and with real-world relevance.<\/p>\n In early 2025, researchers at the Africa Health Research Institute (AHRI)<\/a> and the University of KwaZulu-Natal launched a first-of-its-kind HIV cure trial in Durban. The study enrolled 20 cisgender women between 18 and 23 years old who were part of the FRESH (Females Rising through Education, Support and Health) cohort. All participants had started antiretroviral therapy (ART) very soon after acquiring HIV \u2014 a crucial factor in limiting the virus\u2019s ability to hide in the body.<\/p>\n Once viral suppression was achieved, participants received a combination of two broadly neutralizing antibodies (bNAbs)<\/strong> \u2014 VRC07-523LS and CAP256V2LS \u2014 designed to bind and disable HIV across different strains. They also received vesatolimod<\/a>, a TLR7 agonist, which aims to stimulate the immune system and flush out hidden viral reservoirs.<\/p>\n This \u201cshock and kill\u201d strategy was designed to wake up latent HIV hiding in the body and give the immune system the tools to destroy it. After several doses, the women entered a supervised process known as analytical treatment interruption (ATI)<\/strong> \u2014 where ART is stopped and the immune response is closely monitored.<\/p>\n What followed stunned the research world.<\/p>\n Of the 20 women who participated:<\/p>\n These findings were shared at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI)<\/a> and were hailed as one of the most significant breakthroughs in HIV cure research to date. For the first time, multiple participants \u2014 all young African women \u2014 achieved long-term viral suppression without medication.<\/p>\n All participants continued regular HIV testing<\/a> throughout the ATI phase to monitor viral load, immune activity, and safety. Importantly, no serious adverse events were reported, and none of the participants who rebounded experienced complications related to stopping ART.<\/p>\n While researchers are cautious about using the word \u201ccure,\u201d this study represents what scientists call a functional cure<\/strong> \u2014 a state where the virus is still present in the body but remains undetectable and untransmittable without medication.<\/p>\n This trial sets itself apart in several key ways:<\/p>\n The Durban trial signals a new era of possibility \u2014 where long-term viral suppression might one day be achievable without daily treatment. This is especially meaningful for people in regions where access to lifelong medication is inconsistent.<\/p>\n Until a cure is widely available, people at risk of HIV exposure in Singapore can still rely on timely access to HIV PEP<\/a> and daily PrEP<\/a> as part of a comprehensive prevention plan.<\/p>\n The Durban trial is not alone in pushing the boundaries of HIV cure science. Globally, several research groups are exploring similar methods to achieve ART-free viral control. One such project is the PAUSE Study<\/a> (ACTG\/HVTN\/HPTN 108), which is testing combinations of broadly neutralizing antibodies (bNAbs) in people living with HIV who began ART early.<\/p>\n South African institutions are also leading other cure-focused collaborations. CAPRISA<\/a>, Wits Reproductive Health Institute<\/a>, and the Centre for HIV and STIs<\/a> at NICD are actively contributing to trials that combine immune-based therapies with latency reversal techniques.<\/p>\n These African-led initiatives are helping close the global research gap. For decades, cure research was concentrated in the Global North, using narrow populations and viral subtypes. South Africa is now redefining what inclusive, effective, and scalable HIV research can look like.<\/p>\n Despite encouraging results, several challenges must be addressed before an HIV cure can become mainstream:<\/p>\n Until these barriers are resolved, existing prevention and treatment tools remain essential. This includes regular HIV testing<\/a>, STD screening<\/a>, and consistent HIV treatment<\/a> access.<\/p>\n The HIV cure field is evolving rapidly. Researchers are exploring next-generation tools that may work even better than current approaches:<\/p>\n Community participation will also be key. Inclusive research that involves women, LGBTQ+ people, and communities from the Global South is essential to create interventions that work for everyone \u2014 not just a few.<\/p>\n While a cure is not yet available, Singapore can learn from global developments. The results from South Africa emphasize the need to:<\/p>\nWhy South Africa Matters in HIV Research<\/h2>\n
Inside the Durban Trial: A Global First<\/h2>\n
The Results That Sparked Hope<\/h2>\n
\n
What Makes This Trial Different<\/h2>\n
\n
Beyond Durban: Other Promising Studies<\/h2>\n
Challenges That Still Remain<\/h2>\n
\n
Looking Ahead: What\u2019s Next for HIV Cure Science<\/h2>\n
\n
Why This Matters for Singapore and the World<\/h2>\n